Moore (1995) blames the FDA for letting encainide and flecainide onto the market.
The CAST study compared encainide and flecainide to a placebo and found excess deaths.
Early review of the data by an independent safety monitoring board revealed that 56 of 730 patients given encainide or flecainide had died from some cause or suffered a heart attack, compared with 22 of 730 patients given placebo.
Other FDA-approved anti-arrhythmics exist but are more toxic than encainide and flecainide and have not been tested for their effects on mortality.
05 mL of 3 mg/L encainide (internal standard) and 1 mL of 0.
Diazepam and midazolam would increase the apparent concentration of encainide, the internal standard used in the assay for delavirdine, indinavir, nelfinavir, ritonavir, and saquinavir.
Antiarrhythmics Amiodarone Encainide
Flecainide Mexilitine N-propylamaline Propafenone Sparteine Antidepressants Imipramine Desipramine Amitriptyline Nortriptyline Clomipramine Beta-blockers Propranolol Timolol Bufuralol Metoprolol Neuroleptics Perphenazine Thioridazine Miscellaneous Codeine Debrisoquine 4-OH amphetamine Indoramin Phenformin Table 5.